Study on the Safety and Effectiveness of CTX112 for Treating Difficult or Returning B-Cell Cancers

Sponsor: CRISPR Therapeutics AG

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05643742

Provider View

This clinical trial is testing a new treatment called CTX112 to see if it is safe and effective for patients with B-cell cancers that have not responded to previous treatments or have returned.

Patient Parameters

Program Overview

The study is designed to evaluate the safety and effectiveness of a new treatment called CTX112 in patients with B-cell cancers that have either come back after treatment or have not responded to previous treatments. CTX112 is a type of immunotherapy that uses specially modified immune cells to target and attack cancer cells.

Description

This clinical trial is testing a new treatment called CTX112 for patients with B-cell cancers that have returned or are not responding to treatment. CTX112 is a type of immunotherapy that uses immune cells from a donor, which are then genetically modified in a lab to target cancer cells. The study is being conducted at multiple locations and aims to determine if CTX112 is safe and effective for these patients.

Eligibility Criteria

Inclusion Criteria

  • Must be 18 years or older.
  • Have a B-cell cancer that has returned or is not responding to treatment.
  • Be in good overall health, with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
  • Have good kidney, liver, heart, and lung function.
  • Women who can become pregnant and men must agree to use effective birth control during the study and for at least 12 months after receiving CTX112.

Exclusion Criteria

  • Have had a stem cell transplant from a donor.
  • Have or had cancer spread to the brain or spinal cord.
  • Have a history of seizures, strokes, dementia, or autoimmune diseases affecting the brain.
  • Have an uncontrolled infection or one that requires IV treatment.
  • Have active HIV, hepatitis B, or hepatitis C infections.
  • Have had another cancer in the last 3 years, except for certain skin cancers or other low-risk cancers.
  • Are currently receiving certain cancer treatments close to the time of receiving CTX112.
  • Have a primary immune deficiency or active autoimmune disease requiring treatment with steroids or other immune-suppressing drugs.
  • Are pregnant or breastfeeding.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.